Compare SPDR Gold Trust (GLD) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Mesoblast Limited — how do they compare? SPDR Gold Trust trades at $366.67, while Mesoblast Limited trades at $19.22 (market cap $2.31B). The key difference: Mesoblast Limited is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| GLD | MESO | |
|---|---|---|
52-Week High | $495.90 | $20.96 |
52-Week Low | $300.96 | $11.35 |
Market Cap | — | $2.31B |
Sector | — | Technology |
Enterprise Value | — | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD, tracking physical gold prices, trades at $365.98, down 1.66% amid a bearish technical signal with moving averages indicating selling pressure. Recent U.S. economic data, including jobless claims and inflation figures, influence gold's short-term volatility, while central bank accumulation provides underlying support. The ETF lacks traditional financial ratios as it holds bullion, with performance tied directly to gold market dynamics and macroeconomic factors.
The outlook for GLD hinges on gold's response to Federal Reserve policy and geopolitical tensions, offering a hedge against inflation but facing headwinds from a stronger dollar and rising yields. Risks include interest rate sensitivity and market sentiment shifts, with investors monitoring key resistance near $375 for breakout potential.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
